Tazzyman et al. demonstrated that the use of a CXCR2 antagonist (AZ10397767) was capable of impeding neutrophil infiltration both in vivo and in vitro, which was associated with reduced tumor growth [75]. Here, CXCR2 is linked to neoplasm.